GOVERNOR PATRICK CELEBRATES NEW GENZYME BIOMANUFACTURING FACILITY OPENING IN FRAMINGHAM
FRAMINGHAM – Monday, October 22, 2012 – Governor Deval Patrick today joined Genzyme, a Sanofi subsidiary and the world’s third-largest biotechnology company, at an open house to celebrate the recent opening of the company’s new biomanufacturing facility in Framingham. Genzyme’s ability to locate the facility at Framingham Technology Park was enabled through infrastructure funding from the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick’s ten-year, $1 billion Life Sciences Initiative.
“Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences,” said Governor Patrick. “Genzyme’s new facility represents Massachusetts competing successfully for jobs in advanced manufacturing. I congratulate Genzyme, and appreciate the company’s ongoing commitment to growing in Massachusetts.”
The Massachusetts Life Sciences Center (MLSC) awarded grant funding totaling $14.3 million to the town of Framingham to upgrade its wastewater collection system in conjunction with Genzyme’s large-scale biomanufacturing expansion project. Over the past four years, the Commonwealth has invested more than $300 million in the state’s life sciences cluster, leveraging more than $1 billion in third-party investments and creating thousands of jobs in both construction and in the life sciences. The life sciences industry in Massachusetts is thriving, with more than 52 percent job growth in the biopharma sector since 2001 and more than 80,000 employees working in the life sciences.
Genzyme employs approximately 4,500 people in Massachusetts, with 2,300 employees at the Framingham campus. Approximately 500 of the Framingham jobs are at the new Framingham biomanufacturing facility.
“The state’s commitment to the life sciences, partnership with industry, and the infrastructure grant for Framingham has helped us meet our most important commitment of restoring the supply of medicine to the patients who depend on us,” said David Meeker, M.D., President and CEO of Genzyme. “The investments we have made to improve our Allston manufacturing plant and build the new facility here in Framingham are clear indicators of our commitment to meet that need for people living with rare diseases such as Fabry and Gaucher.”
Earlier this month, Massachusetts hosted the AdvaMed Convention, the annual convention of the U.S. medical device industry. In June, Massachusetts hosted the BIO International Convention, which brought more than 15,000 participants and 3,000 companies to Boston. Both AdvaMed and BIO gave Governor Patrick, Lieutenant Governor Timothy Murray, and state and industry leaders an opportunity to showcase Massachusetts as a global leader in the life sciences industry, and the preeminent place for life sciences companies to invest in and expand. During the BIO convention, Governor Patrick announced innovation partnerships with regions in Spain, and Denmark and Sweden, and the creation of a neuroscience consortium formed by seven companies.
"The Center is pleased to support the town of Framingham through a true public/private partnership that has enabled Genzyme to expand their biomanufacturing efforts in Massachusetts and create hundreds of new jobs,” said Susan Windham-Bannister, Ph.D., President & CEO of the MLSC. “When we support biomanufacturing we create jobs that are available to people with a variety of skills and levels of education attainment. Genzyme is a company built on groundbreaking science that fundamentally changes the lives of patients with rare diseases, such as Fabry’s disease. With the opening of Genzyme’s new biomanufacturing facility we will see therapies reaching patients quicker – and that’s what the Massachusetts life sciences industry is all about.”
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, $1-billion initiative that was signed into law in June of 2008. The Center’s mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties among sectors of the Massachusetts life sciences community. For more information, visit www.masslifesciences.com.